PW Medtech Resumes Push for Sichuan Ruijian Listing on Beijing Stock Exchange

PW Medtech Group Ltd. ( (HK:1358) ) has shared an announcement.

PW Medtech Group has provided an update on the planned subsequent listing of its subsidiary Sichuan Ruijian Medical on the Beijing Stock Exchange, a transaction that would constitute a deemed disposal and possible major transaction for the Hong Kong-listed parent. After Sichuan Ruijian Medical voluntarily suspended the listing review in September 2025 because its financial statements dated 31 December 2024 were nearing the end of their effective period, the company prepared and approved new financials with a cut-off date of 30 June 2025 and submitted an application on 26 December 2025 to resume the review. The Beijing Stock Exchange has now adjusted the review status back to “resumption of review,” signalling renewed regulatory progress, though PW Medtech cautions that completion of the listing still depends on market conditions and approvals from the CSRC and the Beijing bourse, and there is no assurance on timing or certainty of the deal, which could affect the group’s ownership stake and capital structure.

The most recent analyst rating on (HK:1358) stock is a Buy with a HK$1.50 price target. To see the full list of analyst forecasts on PW Medtech Group Ltd. stock, see the HK:1358 Stock Forecast page.

More about PW Medtech Group Ltd.

PW Medtech Group Limited is a Cayman Islands-incorporated medical technology company listed in Hong Kong (Stock Code: 1358). Through subsidiaries including Sichuan Ruijian Medical, it operates in the medical devices and healthcare sector, with a strategic focus on the Chinese market and on leveraging domestic capital markets for its portfolio companies’ development.

Average Trading Volume: 617,949

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.91B

Find detailed analytics on 1358 stock on TipRanks’ Stock Analysis page.